


or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof.

2. Compounds of formula (I), wherein R^1 is a methyl group.
3. Compounds according to claim 1 or claim 2, wherein R^2 is a hydrogen atom or a methyl group.
4. Compounds according to any one of claims 1 to 3, wherein R^3 is a methyl group, a trifluoromethyl group or a group of formula COOH .
5. Compounds according to any one of claims 1 to 4, wherein R^3 is a trifluoromethyl group.
6. Compounds according to any one of claims 1 to 5, wherein R^6 is an optionally substituted 5- or 6-membered heteroaryl radical having 1, 2 or 3 hetero atoms selected from S, N and O.
7. Compounds according to any one of claims 1 to 5, wherein R^6 is an optionally substituted thiazole ring or pyridine ring.
8. Compounds according to any one of claims 1 to 5, wherein R^4 is a group having the following formula:



9. Pharmaceutical composition, which contains a compound according to any one of claims 1 to 8 and optionally one or more carriers and/or one or more adjuvants.
10. Use of a compound or a pharmaceutical composition according to any one of claims 1 to 9 in the treatment of cancer diseases.